Intra-Cellular Therapies, Inc. (ITCI)
NASDAQ: ITCI · Real-Time Price · USD
83.45
-0.69 (-0.82%)
At close: Dec 20, 2024, 4:00 PM
84.32
+0.87 (1.04%)
After-hours: Dec 20, 2024, 4:09 PM EST
Intra-Cellular Therapies Revenue
Intra-Cellular Therapies had revenue of $175.38M in the quarter ending September 30, 2024, with 39.00% growth. This brings the company's revenue in the last twelve months to $613.73M, up 46.08% year-over-year. In the year 2023, Intra-Cellular Therapies had annual revenue of $464.37M with 85.51% growth.
Revenue (ttm)
$613.73M
Revenue Growth
+46.08%
P/S Ratio
13.69
Revenue / Employee
$1,006,111
Employees
610
Market Cap
8.85B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 464.37M | 214.06M | 85.51% |
Dec 31, 2022 | 250.31M | 166.51M | 198.69% |
Dec 31, 2021 | 83.80M | 60.99M | 267.35% |
Dec 31, 2020 | 22.81M | 22.75M | 37,537.14% |
Dec 31, 2019 | 60.61K | - | - |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Dec 31, 2014 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Henry Schein | 12.50B |
Bruker | 3.24B |
Bio-Rad Laboratories | 2.58B |
Bio-Rad Laboratories | 2.58B |
Exelixis | 2.08B |
Masimo | 2.04B |
Penumbra | 1.16B |
Repligen | 633.51M |
ITCI News
- 10 days ago - Intra-Cellular Therapies Presents Data from the CAPLYTA Adjunctive MDD Phase 3 Program at the American College of Neuropsychopharmacology Annual Meeting - GlobeNewsWire
- 13 days ago - Intra-Cellular Therapies: Parkinson's Disease Drug Expansion Could Be The Next Huge Move - Seeking Alpha
- 18 days ago - Intra-Cellular Therapies Submits Supplemental New Drug Application (sNDA) to FDA for CAPLYTA® (lumateperone) for the Treatment of Major Depressive Disorder as Adjunctive Therapy - GlobeNewsWire
- 4 weeks ago - Intra-Cellular Therapies to Participate in Three Upcoming Investor Conferences - GlobeNewsWire
- 6 weeks ago - Intra-Cellular Therapies Announces Presentations at the 2024 Psych Congress and NEI Congress - GlobeNewsWire
- 6 weeks ago - Intra-Cellular's schizophrenia drug meets main goal in late-stage trial - Reuters
- 7 weeks ago - Intra-Cellular Therapies, Inc. (ITCI) Q3 2024 Earnings Call Transcript - Seeking Alpha
- 7 weeks ago - Intra-Cellular Therapies Reports Third Quarter 2024 Financial Results, Provides Corporate Update and Raises 2024 Caplyta Sales Guidance - GlobeNewsWire